Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cancer Cell. 2012 May 15;21(5):614-25. doi: 10.1016/j.ccr.2012.03.042.

    Allele-specific p53 mutant reactivation.

    Source

    The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.

    Abstract

    Rescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National Cancer Institute's anticancer drug screen data, we identified two compounds from the thiosemicarbazone family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53(R175) mutant. Mechanistic studies reveal that NSC319726 restores WT structure and function to the p53(R175) mutant. This compound kills p53(R172H) knockin mice with extensive apoptosis and inhibits xenograft tumor growth in a 175-allele-specific mutant p53-dependent manner. This activity depends upon the zinc ion chelating properties of the compound as well as redox changes. These data identify NSC319726 as a p53(R175) mutant reactivator and as a lead compound for p53-targeted drug development.

    Copyright © 2012 Elsevier Inc. All rights reserved.

    Comment in

    PMID:
    22624712
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3366694
    [Available on 2013/5/25]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk